Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q4 FY19 results · Jan–Mar 2019
Torrent Pharmaceuticals reported revenue from operations of ₹1,856.00 crore and net loss of ₹152.00 crore for Q4 FY19 (Jan–Mar 2019), on a consolidated basis.
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,856.00 | — | — | 2,051.00 | −9.5% |
| Other income | 17.00 | — | — | 3.00 | +466.7% |
| Total income | 1,873.00 | — | — | 2,054.00 | −8.8% |
| Profit before tax | (150.00) | — | — | 275.00 | Turned loss |
| Net profit for the period | (152.00) | — | — | 246.00 | Turned loss |
| EPS, basic (₹) | (8.95) | — | — | 14.50 | Turned loss |
| Net margin (%) | -8.2 | — | 12.0 |
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,357.00 | — | — | 1,481.00 | −8.4% |
| Other income | 227.00 | — | — | 13.00 | 17x |
| Total income | 1,584.00 | — | — | 1,494.00 | +6.0% |
| Profit before tax | 255.00 | — | — | 192.00 | +32.8% |
| Net profit for the period | 164.00 | — | — | 182.00 | −9.9% |
| EPS, basic (₹) | 9.73 | — | — | 10.73 | −9.3% |
| Net margin (%) | 12.1 | — | 12.3 |
Consolidated
- Filed with BSE
- 21 May 2019, 10:25 IST
- Board meeting
- 20 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 21 May 2019, 10:25 IST
- Board meeting
- 20 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE